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Abstract
Rationale: Proteolysis is a key aspect of the lung’s innate immune
system. Proteases, including neutrophil elastase and MMPs (matrix
metalloproteases), modulate cell signaling, inflammation, tissue
remodeling, and leukocyte recruitment via cleavage of their target
proteins. Excessive proteolysis occurs with chronic tobacco use
and is causative for bronchiectasis and emphysema. The effect of
e-cigarettes (vaping) on proteolysis is unknown.
Objectives:We used protease levels as biomarkers of harm to
determine the impact of vaping on the lung.
Methods:We performed research bronchoscopies on healthy
nonsmokers, cigarette smokers, and e-cigarette users (vapers), and
determined protease levels in BAL. In parallel, we studied the effects
of e-cigarette components on protease secretion in isolated human
blood neutrophils and BAL-derived macrophages. We also analyzed
the nicotine concentration in induced sputum and BAL.
Measurements and Main Results: Neutrophil elastase, MMP-2,
and MMP-9 activities and protein levels were equally elevated in
both vapers’ and smokers’ BAL relative to nonsmokers. In contrast,
antiprotease levels were unchanged. We also found that exposure
of isolated neutrophils and macrophages to nicotine elicited
dose-dependent increases in protease release. After vaping,
measurable levels of nicotine were detectable in sputum
and BAL, which corresponded to the half-maximal
effective concentration values for protease release seen in
immune cells.
Conclusions:We conclude that vaping induces nicotine-dependent
protease release from resident pulmonary immune cells. Thus,
chronic vaping disrupts the protease–antiprotease balance by
increasing proteolysis in lung, which may place vapers at risk of
developing chronic lung disease. These data indicate that vapingmay
not be safer than tobacco smoking.
Keywords: vaping; protease; BAL; sputum; nicotine
Tobacco smoking is responsible for chronic
respiratory disease, cardiovascular disease,
and several types of cancer (1). Electronic
nicotine delivery systems (i.e., e-cigarettes)
are noncombustible tobacco alternatives
that aerosolize nicotine and flavoring agents
in a propylene glycol and vegetable glycerin
(PG/VG) vehicle. They were originally
envisaged as a tobacco cessation tool (2),
but whether or not they help people to quit
tobacco use is unclear (3–5). Vaping
e-cigarettes has been perceived by the
general public and some professional
bodies as a safer alternative to tobacco
smoking (6), and a recent report from
Public Health England reiterated previous
advice that e-cigarettes are 95% safer than
smoking and that people should switch
from tobacco to e-cigarettes (7). However,
this is controversial because there are
conflicting data regarding their safety and,
to date, no robust long-term exposure data
exist (8, 9). In contrast, a recent European
Respiratory Society task force concluded
that, because the long-term effects of
vaping are unknown, there is no evidence
that they are safer than tobacco and that,
based on current knowledge, negative
health effects cannot be ruled out (10).
Given that some professional bodies are
now recommending e-cigarettes as a safe
alternative to tobacco and are asking for
them to be prescribed clinically (11), it is
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imperative to understand whether or not
they are actually safer than conventional
tobacco products.
Proteolysis is a form of post-translational
modification that can degrade unwanted
proteins and/or modify protein function
(12, 13). As such, there are multiple proteases
present both intracellularly and extracellularly
whose activity is tightly regulated by a series of
antiproteases for overall positive benefit. In
the lung, changes in proteolysis do not
necessarily result in detrimental outcomes.
For example, these changes can alter
antimicrobial activity, airway hydration and
mucus clearance, inflammation, and cell
signaling, and can facilitate tissue turnover as
part of normal homeostasis. However, during
multiple types of chronic lung disease,
protease–antiprotease imbalance occurs, and
the subsequent increase in proteolysis
contributes to pathogenesis (14–17). The
association between combustible tobacco
products and increased proteolysis has been
well established (18–20), and previous studies
revealed enhanced protease levels and activity
in the lungs of cigarette smokers (21–24).
For example, increased MMP (matrix
metalloprotease) expression and basement
membrane degradation has been shown in
smokers and patients with chronic obstructive
pulmonary disease (COPD) (25). Similarly,
increased proteolysis drives bronchiectasis in
cystic fibrosis, lung disease, and in alpha-1
antitrypsin deficiency (26, 27). Abnormal
proteolysis also plays a role in tumor
progression and metastasis by facilitating
tissue remodeling (28).
Recently, it has been demonstrated that
chronic e-cigarette use alters the bronchial
proteome (29). E-cigarette use has also been
linked with immunosuppression in the upper
airways and enhanced levels of detoxifying
proteins and mucins in sputum (30, 31).
Inhaled e-liquid aerosols are thought to be
deposited in the bronchoalveolar region (32).
Therefore, we postulated that secreted
proteases could serve as well-validated
biomarkers of harm because they are causal
for the development of chronic lung disease
when in imbalance with antiproteases.
However, limited information is available on
the actual effects of chronic e-cigarette use on
the protease–antiprotease balance of vapers’
lungs. Thus, we tested the hypothesis that
chronic e-cigarette exposure leads to similar
increases in secreted lung proteases as seen
with chronic tobacco exposure. To test this
hypothesis, we performed research
bronchoscopies on “never-smokers,” current
tobacco smokers, and a cohort of e-cigarette
users that included both never-smokers and
former tobacco smokers. We measured BAL
protease levels. In parallel, we also studied the
effects of e-liquid components on protease
secretion from relevant immune cells in vitro.
Methods
Study Design
We performed research bronchoscopy on
nonsmokers, smokers, and vapers as
previously published (29). All subjects
provided informed consent and completed a
smoking diary to document tobacco product
use in the last 2 weeks prior to sample
acquisition. Details of sample acquisition are
provided in the online supplement.
Protease Evaluation in BAL Samples
The relative expression level of different
proteases was evaluated using Western
blotting of concentrated BAL in age-
matched subjects. For measurement of
protease activity in BAL samples, we used
fluorescent peptides. MMP-2/9 activity was
also evaluated using zymography. Details
are provided in the online supplement.
Statistical Analysis
All the data sets were checked for normal
distribution. Parametric or nonparametric
analysis was chosen based on the
distribution of the data; one-way ANOVA
was used to compare the groups, and P <
0.05 was considered significant. The specific
post hoc tests used are reported in figure
legends. GraphPad Prism software was used
to measure the half-maximal effective
concentration (EC50) values by plotting log
concentration of nicotine with the
measured outcome.





We performed research bronchoscopies on
healthy subjects, including never-smokers,
cigarette smokers, and e-cigarette users
(vapers) as described (29). All subjects
completed a smoking diary and
questionnaire to determine their current and
former smoking and vaping habits. Subject
demographics and smokin and vaping habits
are shown in Tables 1 and E1 in the online
supplement, respectively. No significant
difference in subject demographics or lung
function was observed between groups. All
nonsmokers were never-smokers, and all
tobacco smokers had significant and regular
cigarette use. Nine out of 14 vapers had a
history of former tobacco use and had
switched to e-cigarettes for at least 6 months
prior to bronchoscopy, and the remainder
were never-smokers. To confirm tobacco
and vape use, we measured serum levels of
nicotine, cotinine, and hydroxycotinine. For
nonsmokers, these compounds were at or
below the limit of detection (Table E2). As
previously described (29), serum from
smokers and vapers had significantly
increased levels of nicotine and its
metabolites compared with nonsmokers,
and no significant differences in metabolite
levels were observed between smokers and
vapers (see Table E2). We also performed
cytological analysis of BAL. Immune cell
numbers were not different across the
groups, indicating that we were studying
smokers and vapers who did not have
significant pathology (see Table 1).
BAL from Smokers and Vapers
Exhibit Increased Neutrophil Elastase
and MMP Levels but Unchanged
Protease Inhibitor Levels
We performed Western blot analysis to
determine the relative levels of NE
At a Glance Commentary
Scientific Knowledge on the
Subject: The effects of combustible
tobacco products on lung
protease–antiprotease balance are well
known. However, the effects of
chronic e-cigarette use (vaping) on the
protease–antiprotease balance in the
lung are poorly understood.
What This Study Adds to the Field:
We demonstrate that vapers’ lungs
have elevated levels of neutrophil
elastase, MMP-2, and MMP-9 with no
change in antiprotease levels. In vitro
exposure of neutrophil and
macrophages to nicotine elicited
protease release. Vaping resulted in
sputum and BAL nicotine
concentrations sufficient to cause
protease release from macrophages.
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(neutrophil elastase), MMP-2, and MMP-9
in BAL. These data were normalized to
albumin as loading controls. NE, MMP-2,
and MMP-9 protein levels were significantly
elevated in both smokers and vapers
compared with nonsmokers (Figures
1A–1D). These increases were sex
independent, and there was no significant
difference in protease levels between vapers
and smokers. We next evaluated BAL
antiprotease levels. Accordingly, we probed
for antiproteases; namely, alpha-1
antitrypsin and secretory leukocyte
protease inhibitor, which can both inhibit
NE; and tissue inhibitors of MMP-1 and
MMP-2, which can inhibit MMPs. Despite
seeing significant increases in NE and
MMP levels in smokers’ and vapers’ BAL,
we did not detect any significant changes in
protease inhibitor levels (see Figures 1E–1I).
Because many vapers have previously used
tobacco products, one cannot be sure
whether any observed changes were due
to current vaping or prior tobacco use.
However, 5 out of 14 vapers reported that
they had never used tobacco products
before becoming e-cigarette users (see Table
E1). We therefore assessed their levels of
NE, MMP-2, and MMP-9 protein levels
relative to nonsmokers. Despite their lack
of prior cigarette use, all three proteases
were significantly elevated relative to
nonsmokers, indicating that the increase in
BAL protease levels was caused by vaping
rather than first-hand exposure to tobacco
(Figure E2).
Protease levels were elevated, whereas
antiprotease levels were unchanged,
suggesting that net protease activity had
increased. Accordingly, we then tested for
changes in BAL protease activity using two
orthogonal approaches. First, we
measured gelatinolytic activity using
zymography. Because MMP-2 andMMP-9
proteases are collagenases that can
degrade basement membranes, we
measured their ability to cleave a gelatin
gel. Indeed, both smokers and vapers
showed significantly increased activity
relative to nonsmokers (Figure 2). Again,
these increases were sex-independent and
not different between smokers and vapers.
Second, we compared MMP-2 and MMP-
9 activity in BAL from vapers who never
smoked versus nonsmokers and again
found that they were significantly
increased (see Figure E2).
Next, we measured the ability of
endogenous BAL proteases to cleave
peptide-based fluorogenic substrates that
were specific to 12 different proteases (Table
E3 and Figure E3) in a subset of BALs that
were sex-matched and age-matched (Table
E4). All protease activities were normalized
to the total BAL protein content. The
peptide dinitrophenyl-Pro-Leu-Gly-Met-
Trp-Ser-Arg is cleaved by both MMP-2 and
MMP-9, and cleavage of this peptide was
significantly upregulated in both vapers and
smokers (see Figure E3A). NE cleaves Suc-
Ala-Ala-Ala-MCA and, similarly, cleavage
was significantly upregulated in both vapers
and smokers (see Figure E3B). In contrast,
cathepsin B activity was elevated only in
smokers compared with nonsmokers (see
Figure E3C). No differences were observed
in the activities of the other proteases tested
(see Figures E3D–E3I), and again no
sex-dependent differences were observed
(see Figures E3A–E3I).
Nicotine Induces Protease Secretion
in Human Neutrophils and
Macrophages In Vitro
Neutrophils and macrophages are two
major inflammatory cell types involved in
lung defense (33). We did not observe
significantly altered cell counts or
neutrophilia in either vapers or smokers
BAL (see Table 1), suggesting that the
increased protease levels (see Figures 1
and 2) were not simply due to altered
immune cell numbers. Therefore, to
understand how vaping leads to elevated
protease levels in vapers’ BAL, we exposed
isolated immune cells to e-cigarette
components. Because neutrophil numbers
were low in our BAL samples, we isolated
peripheral blood neutrophils by negative
magnetic selection and immediately
exposed them to the base e-liquid
components; that is, PG/VG in a 55:45
volume/volume ratio 618 mg/ml nicotine
or an equivalent amount of nicotine in
media. We exposed neutrophils to e-liquid
components for 4 hours, as indicated, and
subsequently collected the media to
measure NE and GAPDH levels by
Western blot. Elevated levels of NE and
GAPDH were detected in the media of
neutrophils incubated with 3% PG/VG
and nicotine, or with nicotine alone
(Figures 3A and 3B). Further confirmation
of NE release was obtained via the
fluorogenic substrate assay, and we
observed significantly increased NE
activity after exposure to 3.3 mM nicotine
(see Figure 3C). This response was also
independent of PG/VG. The presence of
GAPDH in the media after treatment with
nicotine (see Figures 3A and 3B) were
indicative of possible neutrophil lysis.
Three percent PG/VG has a concentration
of 408 mM, which when added to media
caused an increase in osmolarity from
approximately 300 mOsm (media alone)
to greater than 700 mOsm. Because
hyperosmotic solutions can cause osmotic
stress and/or cell lysis, we also treated
neutrophils to media with 408 mM
mannitol as an osmotic control (Table
E5). However, despite the increase in
osmolarity, the mannitol control did not
affect NE levels (see Figures 3A–3C).
Because primary BAL macrophages
and peripheral blood neutrophils do not
culture well for extended periods, we then
Table 1. Subject Demographics and Cytology Analysis of BAL Samples
Nonsmokers Smokers Vapers




Age at bronchoscopy, yr 25.7967.29 29.5065.59 26.0768.30
Height, cm 165.4667.97 171.86611.42 172.7068.35
Weight, kg 72.47621.51 82.04618.63 88.73620.35
Body mass index, kg/m2 26.1765.87 27.8466.05 29.7966.60
FVC, % predicted 100.65622.47 110.5068.72 100.6468.69
FEV1, % predicted 102.86613.51 106.3669.43 100.0766.96
Polymorphonuclear cells, % 2.8862.61 1.9961.69 3.1362.58
Eosinophils, % 0.4760.94 0.2660.43 0.3260.48
Lymphocytes, % 0.0760.17 0.0060.00 0.0060.00
Bronchial epithelial cells, % 0.4760.65 0.1960.33 0.4660.65
Squamous epithelial cells, % 0.1760.25 0.3060.42 0.1760.23
Macrophages, % 96.1162.40 97.5661.78 96.1062.89
Data were provided as mean6SD except where otherwise indicated.
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studied the effects of overnight incubation
with PG/VG plus or minus nicotine on
differentiated Tohoku Hospital Pediatrics-1
cells, a macrophage-like cell line. We
observed an increase in MMP-2/9 activity in
the media after an overnight exposure of 1%
PG/VG with 1.8% nicotine (Figure E4),
suggesting that this phenomenon persisted
after chronic exposure.
Nicotine Increases Cytosolic Ca21
Levels and Induces Protease Release
from BAL Macrophages and
Peripheral Blood Neutrophils in a
Dose-Dependent Manner
Nicotinic acetylcholine receptors are cation-
permeable, ligand-gated ion channels, and
their stimulation by nicotine increases
cytosolic Ca21 levels (34). Importantly,
Ca21 is a key second messenger that
induces secretion of proteins, including
proteases, into the extracellular
environment. We exposed neutrophils and
alveolar macrophages to a range of nicotine
concentrations and determined the
subsequent changes in cytoplasmic Ca21
and protease secretion. Addition of nicotine




































































































































































































































Figure 1. Protease protein levels are equally increased in vapers’ and smokers’ BAL. (A) Representative Western blots showing increased protease
protein in smokers’ and vapers’ BAL, along with albumin as loading control. Full blots are provided in Figure E1. (B–D) Densitometric analysis of total
protease levels normalized to albumin for neutrophil elastase (B), MMP-2 (matrix metalloprotease-2) (C), and MMP-9 (D). (E) Representative Western blots
of BAL protease inhibitors. (F–I) Densitometric analysis of BAL normalized to albumin control for A1AT (alpha-1 antitrypsin) (F), SLPI (G), TIMP1 (tissue
inhibitor of metalloproteinases-1) (H), and TIMP2 (I). Values are log2 fold change in smokers and vapers compared with age-matched nonsmokers; *P <
0.05 and **P< 0.001. Pink, female subjects; blue, male subjects. Data are shown as mean6SD. All n=14 subjects per group. Data were analyzed using
ANOVA followed by Tukey’s test. SLPI = secretory leukocyte protease inhibitor.
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cytoplasmic Ca21 levels with a calculated
EC50 of 210 mM (Figures 4A and 4B).
Thapsigargin is a sarcoendoplasmic
reticulum Ca21-ATPase inhibitor that
increases cytoplasmic Ca21, which we used
as a positive control (see Figure 4A).
Thapsigargin increased cytoplasmic Ca21
levels to similar extent as nicotine. We also
evaluated NE release 3 hours after nicotine
exposure. Nicotine stimulated NE release
from neutrophils with an EC50 of 3.9 mM
(see Figure 4C). Macrophages showed
more sensitivity to nicotine for both the
Ca21 response and protease release (see
Figures 4D–4F). After nicotine addition, a
rapid increase in cytosolic Ca21 occurred
with an EC50 of 96.4 mM that was also
similar in magnitude to the effects of
thapsigargin (see Figures 4D and 4E).
However, protease release from
macrophages showed more sensitivity to
nicotine, and the EC50 for MMP-2/9 release
was 37.4 nm (see Figure 4F). Because
both cell types showed dose-dependent
responses to nicotine, we then used
quantitative PCR to look for expression
of several nicotinic acetylcholine receptors
(nAChRs). Neutrophils expressed CHRNB1
(cholinergic receptors nicotinic subunit B1),
CHRNA5, and CHRNA6 (see Figure 4G).
In addition to these receptors, macrophages
also expressed CHRNA7 (see Figure 4H).
Evaluation of Nicotine, Cotinine, and
Hydroxycotinine in the Lungs of
Vapers
Because nicotine was the key factor for
protease release from inflammatory cells, we
measured nicotine concentrations in vapers
sputum under real-life conditions; that is,
immediately after a vape session, using a
mass spectrometry-based method (see
online supplement). Table E6 shows the
demographic details of the volunteers, their
choice of e-liquid, and their vaping patterns
before sputum induction. We focused on
the identification of nicotine and its two
major metabolites; namely, cotinine and
hydroxycotinine (35). As expected, the
amount of detectable nicotine, cotinine, and
hydroxycotinine was negligible in the
sputum from control subjects (Figures
5A–5C and see Table E6). In contrast,
nicotine was significantly elevated in vapers
sputum. Cotinine and hydroxycotinine
were also significantly elevated but were
present at lower levels, suggesting that
significant nicotine metabolism did not
occur in the lung lumen (see Figures
5A–5C). BAL samples from nonsmokers
and vapers also exhibited significant
amounts of nicotine and cotinine (see
Figures E6A–E6C). Importantly, the
mean nicotine concentration in sputum
(z45 mM) (see Figure 5A) and BAL
(z3 mM) (see Figure E6A) were sufficient





































Figure 2. Total gelatinolytic activities are increased in vapers’ BAL. Gelatinolytic activity was
measured in BAL samples by zymography. (A) Inverted image of representative zymogram showing
increased MMP (matrix metalloprotease) activity in smokers’ and vapers’ BAL samples. (B)
Quantification of gelatinolytic activity by MMP, shown as log2 fold change, compared with age-
matched nonsmokers. Individual activities of MMP-2 and MMP-9 are shown in Figure E4. **P <
0.001. Pink, female subjects; blue, male subjects. Data are shown as mean6SD. All n=14 subjects



























































































































Figure 3. Nicotine, but not propylene glycol and vegetable glycerin (PG/VG), induces neutrophil elastase (NE) release from neutrophils. Neutrophils were
isolated from peripheral blood and exposed to combinations of PG/VG, nicotine or mannitol (osmotic control) for 4 hours. (A) Representative Western blots
of neutrophil secretions after incubation with the indicated e-liquid components, with Ponceau S staining as a loading control. (B) Densitometric analysis of
NE and GAPDH normalized to Ponceau S staining shown as fold change compared with control. (C) NE activity in concentrated media, as measured using
the fluorogenic substrate assay. *P < 0.05 and **P < 0.001. Data are shown as mean6SEM. All n=12 per group. Data were analyzed using ANOVA
followed by Tukey’s test. AU=arbitrary units; MAN=mannitol; NIC=nicotine.
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Discussion
Here, we have focused on the effects of
vaping e-cigarettes on pulmonary
(i.e., BAL) protease levels because the link
between increased proteolysis and disease
is well established (36). NE is a serine
protease with a broad substrate specificity
that is important for host defense. We
found that both total NE protein levels
and NE functional activity were elevated
in both smokers and vapers (see Figures
1A and 1B and E3). In contrast, the NE
secretory leukocyte protease inhibitor was
unchanged, indicating that the increased
NE-dependent proteolysis was due to
higher NE levels rather than a decrease
in inhibitor levels. Importantly, the
elevation in NE levels was 1) similar
between vapers and smokers (see Figures
1A and 1B) and 2) was also seen in vapers
who were never-smokers (see Figure E2),
indicating that this change was caused by
chronic vaping and was not simply a
residual effect from smoking.
Elevated lung NE levels and activity
are seen in alpha-1 antitrypsin
deficiency, an inherited condition in
which individuals lack a key protease



























































































































































































Figure 4. Nicotine causes dose-dependent increases in cytoplasmic Ca21 and induces protease release from immune cells. Neutrophils and
alveolar macrophages were loaded with the calcium indicator dye Fluo-4 direct and the change in fluorescence, as an indicator of cytoplasmic Ca21,
was recorded over time. The media was then sampled 4 hours after exposure to measure protease activity, as indicated by changes in cleavage of
fluorogenic substrates specific to neutrophil elastase (NE) and MMP-2/9 (matrix metalloprotease-2/9). (A) Changes in Fluo4 fluorescence, as an
indicator of cytoplasmic Ca21 levels over time in peripheral blood neutrophils. (B and C) Dose responses to nicotine exposure in neutrophils for peak
(2 min) increases in cytoplasmic Ca21 levels and 3 hours secreted NE activity, respectively; n = 9 per group. Data were normalized to GAPDH
expression; n = 8 per group. (D) Changes in Fluo-4 fluorescence, as an indicator of cytoplasmic Ca21 levels, in BAL macrophages. (E and F) Dose
responses to nicotine exposure in BAL macrophages for peak (2 min) increases in cytoplasmic Ca21 levels after nicotine exposure and secreted NE
activity, respectively; n = 9 per group. (G) Nicotinic acetylcholine receptor expression in peripheral blood neutrophils, as measured by quantitative
PCR (qPCR). (H) Nicotinic acetylcholine receptor expression in alveolar macrophages, as measured by qPCR; n = 8 per group. *P < 0.05
compared with control. Data are shown as mean6SEM. Data were analyzed using Mann-Whitney U test (A and E) or fit to the equation
Y=bottom1 (top2bottom)/(11 10X2 logIC50) (B, C, F, and G). AU=arbitrary unit; DCT=delta cycle threshold; CHRN=cholinergic receptors nicotinic
subunit; EC=effective concentration; F/F0= ratio of final to initial fluorescence; TG= thapsigargin.
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Patients with alpha-1 antitrypsin
deficiency typically develop COPD-like
symptoms, including emphysema, by their
mid-40s (26). Due to unremittent
infection and inflammation, NE levels are
also extremely high in the lungs of
patients with cystic fibrosis, and this
increase correlates with a greater decline
in FEV1 (37). Furthermore, instillation of
supernatant from cystic fibrosis sputum
into rat lungs caused rapid hemorrhaging
that was attenuated by pretreatment with
a NE inhibitor, thus illustrating the
damaging effect of high NE levels (38). NE
levels are also upregulated in patients with
COPD (39). Interestingly, NE knockout
(ELANE2/2) mice were protected from
developing emphysema despite being
exposed to chronic tobacco smoke, which
also indicates a causal link between NE
and lung damage (18).
We also detected increased MMP2
and MMP-9 levels and activity in vapers’
BAL using 3 independent techniques;
namely, Western blotting, the
fluorogenic substrate assay, and by
zymography (see Figures 1A–1D, 2A–2C,
and E3). Again, despite being elevated,
MMP-2 and MMP-9 levels were not
different between smokers and vapers, and
were seen at similar levels in vapers who
never smoked (see Figures 1A–1D, 2A–2C,
and E2). MMP-2 and MMP-9 (also known
as gelatinase a and b, respectively) are also
implicated in disease. MMP-2 levels are
elevated in smokers, especially in those
with COPD, and this increase inversely
correlates with FEV1 (40, 41). Wells
and colleagues demonstrated elevated
MMP-9 levels in sputum from patients
with COPD that correlated with an
increased incidence of acute exacerbation
(42). MMP-2 and MMP-9 levels are also
upregulated in sputum from people with
asthma (43) and MMP-9 is elevated in
BAL from people with cystic fibrosis,
which also inversely correlates with
lung function (44). Interestingly, serum
MMP-9 levels also correlate with
COPD disease severity (45). Thus,
protease levels, and MMPs in particular,
may be a useful biomarker for chronic
vaping that can be applied to larger
populations.
To date, the effects of chronic
e-cigarette use on the lung are poorly
characterized. Reidel and colleagues
recently performed proteomics on vapers’
sputum (31). Sputum reflects a different
compartment than BAL and is more
representative of the surfaces of central
and large airways, rather than the small
distal airways and alveolar regions.
However, these researchers found more
protein changes in vapers’ than in
smokers’ sputum relative to nonsmokers.
Importantly, they detected upregulation of
NE and MMP-9 protein levels in vapers’
sputum, although they did not measure
protease activity. Their data also suggested
that vapers’ neutrophils were altered, and
they found increased evidence of
neutrophil extracellular trap release, so-
called NETosis, in vapers’ neutrophils. In
this previous study, all of the vapers were
ex-smokers and there is the possibility
that some effects seen in vapers were
due to the previous tobacco exposure.
However, Garcia-Arcos and colleagues
exposed naı̈ve mice to PG/VG and
nicotine for 4 months (46), which caused
significant emphysema. Although they did
not measure murine lung protease activity
per se, tobacco exposure–induced
emphysema is dependent on increased
proteolysis (46), making it likely that
vaping increased protease activity in
these mice.
To better understand how vaping
led to increased proteolysis, we exposed
inflammatory cells to various e-liquid
components in vitro. Nicotine induced
protease release from neutrophils that
was independent of PG/VG and was
not an osmotic effect (see Figure 3).
Interestingly, we detected GAPDH in the
culture media, suggesting that some cell
lysis may have occurred. Although the
interaction between nicotine and
neutrophils has not been extensively
studied, nicotine has been previously
shown to increase NE gene and protein
expression in human leukemic–60 cells (47,
48). Garcia-Arcos and colleagues concluded
that vape-induced emphysema was driven
by nicotine rather than by other e-liquid
components such as PG/VG (46). Similarly,
Scott and colleagues found that nicotine
contained in e-cigarettes exerted
proinflammatory effects on human alveolar
macrophages (49). In vitro exposure of
neutrophils to nicotine has also been shown
to increase NE gene expression and












































































































Figure 5. Measurements of nicotine and its metabolites in vapers’ sputum. Vapers were asked to vape normally over 1 hour, and sputum was induced
immediately afterwards. Metabolite levels were then measured by gas chromatography–mass spectrometry. (A–C) Graphs show concentrations of
nicotine (A), cotinine (B), and hydroxycotinine (C), from control subjects (n=6) and vapers (n=8). Nicotine concentrations are shown as both micromolar
(left) and milligrams per milliliter (right). Data are shown as mean with range along with individual data points and P values. Data were analyzed using the
Mann-Whitney U test. OH-Cotinine = hydroxycotinine.
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has also been shown to cause upregulation
of MMP-2 and MMP-9 in the murine
macrophage cell line RAW 264.7 (51).
Thus, it is likely that nicotine is directly
exerting effects on multiple immune cell
types.
Ca21 is an important second
messenger that, when elevated, can acutely
trigger secretion of proteins, including
proteases and cytokines (52, 53).
Interaction between nicotine and nAChR
leads to cellular Ca21 influx (54).
Consistent with this well-established
interaction between nicotine and its
receptor, here we found that nicotine
elicited an increase in cytoplasmic Ca21 in
both neutrophils and macrophages with
EC50s of 210 and 94 mM, respectively.
We also demonstrated that nicotine
caused an increase in protease activity in
the media of both cell types. Interestingly,
the EC50 for protease release from
neutrophils (3.9 mM) was somewhat
higher than for the Ca21 response
(210 mM) and, given that we observed
GAPDH in the media, we speculate that
protease release from neutrophils may
have occurred subsequent to cell lysis and
NETosis. However, the EC50 for protease
release from alveolar macrophages was
approximately 40 nm, suggesting that we
had observed regulated, Ca21-dependent
protease secretion, rather than lysis (see
Figure 4). Although both cell types
expressed several subtypes of nAChR,
only alveolar macrophages expressed
CHRNA7 (see Figure 4). Although many
nAChRs express as heteromultimers,
CHRNA7 expresses as a homotetramer,
and we propose that its presence leads to
the increased sensitivity to nicotine in
macrophages. Of note, CHRNA7 has
recently been shown to modulate the
lung’s response to inflammation and
tobacco smoke in a murine model,
suggesting that its expression is
physiologically relevant during the
inflammatory response to tobacco
smoke (55).
The nicotine concentration in serum
and urine has been well studied (56).
However, considerably less is known
about nicotine levels in the lung
immediately after smoking or vaping. We
previously found that nicotine in cigarette
smokers’ sputum was approximately
30 mM within approximately 30 minutes
after smoking (57). Because the levels of
vape and nicotine exposure in vapers’
lungs were unknown, we measured
nicotine within a similar timeframe
(i.e., z30 min) after vaping. Here, we
studied both sputum and BAL. We found
that vaping led to a significant increase in
nicotine and other metabolites, and that
nicotine was present at a similar level as
seen in smokers’ sputum (z50 mM).
Nicotine was also present in vapers’ BAL
at approximately 3 mM. Nicotine is
extremely concentrated in e-liquids and,
in our study, freebase nicotine ranged
from 3 to 12 mg/ml, which equates to
18.52 to 74.07 mM. Uncharged nicotine is
cell-permeable, which is how it reaches
systemic circulation. Thus, it is likely that
we are measuring nicotine as it is being
transepithelially absorbed down its
chemical gradient into the body, and we
speculate that much higher levels of
nicotine are initially seen in vapers’
airways during actual inhalation; that is,
in the period before we could induce
sputum. Furthermore, sputum and BAL
were obtained at least 30 minutes and 2
hours, respectively, after the subjects’ last
vape sessions, as necessitated by the
sputum induction and bronchoscopy
procedures, which may explain the
lower nicotine levels. Importantly, the
concentration of nicotine measured in
vapers’ airways was sufficient to elicit
protease release from relevant immune
cell types in comparison (see Figures 4, 5,
and E6). Our data implicate nicotine in
the release of potentially damaging
proteases into the lung lumen. Beyond
the potential for altering the lung,
nicotine is also highly addictive and
desensitization of nAChR in the brain
provides nicotine’s psychotropic effects.
Of concern is the increase in vaping in
adolescents, suggesting that more young
people are being exposed to nicotine (58).
Crucially, nicotine affects neuronal
development in adolescents (59) and can
also serve as a gateway to further addition.
For example, in a murine model,
pretreatment with nicotine increased the
propensity for cocaine addiction but not vice
versa, suggesting that this is a nicotine-
specific effect (60).
There are a few limitations of our
study. First, although we were adequately
powered, the number of subjects in this
study was relatively small and, owing to
the potential importance of our findings,
we propose that lung protease levels need
to be assessed in a larger population.
Second, for the in vitro portion of the
study, we studied only two cell types
(see Figures 3, 4, and E5) and other cell
types, including airway epithelia, may also
contribute to nicotine-induced protease
release (61, 62). Finally, some vapers in
our study were ex-smokers and, although
they switched from combustible tobacco
to e-cigarettes at least 6 months prior to
sample collection, there may be a residual
effect of smoking. As a counterpoint to
this, Zhang and colleagues previously
demonstrated that many genes return to
baseline after smoking cessation (63),
suggesting that the study of former
smokers is valid. Despite these potential
limitations, increased protease levels and
activities were observed in e-cigarette users
regardless of their former smoking status,
suggesting that continued vaping may be a
significant risk to pulmonary health.
Indeed, given the role of proteases in lung
damage and remodeling, it is possible that
chronic vaping may pose a risk of
emphysema and/or bronchiectasis.
Because these ultrastructural changes
often occur before changes can be
detected by pulmonary function tests, we
also propose that healthy, chronic vapers
be studied using lung-imaging techniques
to better understand the potential risk
that vaping may pose to lung health.
Given the established link between
proteolysis and lung disease, long-term
studies on the effects of continued use of
e-cigarettes should be conducted before
prescribing them as a safer alternative
to smoking. Certainly, from a lung
perspective, and based on lung proteases as
an endpoint, it is hard to understand how
they can be classified as being 95% safer
than tobacco smoking, as has previously
been stated (64). n
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